Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Stock Chart & Stats
$28.85
-$0.14(-8.75%)
At close: 4:00 PM EST
$28.85
-$0.14(-8.75%)
Day’s Range― - ―
52-Week Range$5.67 - $42.39
Previous CloseN/A
Volume421.15K
Average Volume (3M)274.25K
Market Cap
$708.83M
Enterprise Value$49.82M
Total Cash (Recent Filing)$157.34M
Total Debt (Recent Filing)$2.60M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 05, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding24,871,128
10 Day Avg. Volume231,180
30 Day Avg. Volume274,254
Financial Highlights & Ratios
PEG Ratio-0.86
Price to Book (P/B)2.71
Price to Sales (P/S)0.00
P/FCF Ratio-6.18
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-249.08
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$64.38Price Target Upside123.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsRAPT disclosed highly encouraging topline data from the Phase 2 trial of ozureprubart in chronic spontaneous urticaria.
Financial StabilityFollowing the positive results, RAPT raised $250M in gross proceeds from a stock offering, which should help operations into mid-2028.
Market OpportunityThere is a large-market opportunity in food allergy for RAPT, supported by a nationwide survey of Americans with food allergy and feedback from practicing allergists.
Bears Say
Clinical Trial ExpectationsA less impactful second readout from Jeyou in asthma is expected, which is a smaller Phase 2a study not powered for efficacy endpoints.
Financial PerformanceRAPT reported a net loss of $17.6M, or $0.65/share, in Q3 2025, compared to a net loss of $18.4M, or $3.79/share, in Q3 2024.
Price Target AdjustmentThe price target has been adjusted from $51 to $38, reflecting updated model assumptions including the removal of the oncology program.
RAPT Therapeutics News
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $5.67 and its highest was $42.39 in the past 12 months.
What is RAPT Therapeutics’s market cap?
RAPT Therapeutics’s market cap is $708.83M.
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 104 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.978 by $0.328.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -0.75.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 24,871,128 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.978. Following the earnings report the stock price went up 2.724%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Currently, no hedge funds are holding shares in RAPT
RAPT Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.38 (123.15% Upside)
$64.38 (123.15% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 69.9%
Last 30 Days ▲ 69.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.01%
12-Months-Change
Fundamentals
Return on Equity
-85.37%
Trailing 12-Months
Asset Growth
40.28%
Trailing 12-Months
Company Description
RAPT Therapeutics
RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for oncology and inflammatory diseases. Based in the United States, RAPT employs its proprietary drug discovery and development engine to create highly selective oral therapies aimed at key points in the immune system. The company’s lead product candidates include RPT193 and FLX475, which are designed to target specific pathways involved in the regulation of immune cells.
RAPT Stock 12 Month Forecast
Average Price Target
$64.38
▲(123.15% Upside)
Technical Analysis
Neurogene
―
DBV Technologies SA - American
―
Autolus Therapeutics
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
7.36% Insiders
4.11% Mutual Funds
36.42% Other Institutional Investors
49.36% Public Companies and
Individual Investors